Korro Bio - Latest News and Information
  • All Technology
  • AI
  • Autonomy
  • B2B Growth
  • Big Data
  • BioTech
  • ClimateTech
  • Consumer Tech
  • Crypto
  • Cybersecurity
  • DevOps
  • Digital Marketing
  • Ecommerce
  • EdTech
  • Enterprise
  • FinTech
  • GovTech
  • Hardware
  • HealthTech
  • HRTech
  • LegalTech
  • Nanotech
  • PropTech
  • Quantum
  • Robotics
  • SaaS
  • SpaceTech
AllNewsDealsSocialBlogsVideosPodcastsDigests

Technology Pulse

EMAIL DIGESTS

Daily

Every morning

Weekly

Sunday recap

NewsDealsSocialBlogsVideosPodcasts
HomeKorro Bio
Korro Bio logo

Korro Bio

0 followers

KRRO

Performance

About Korro Bio

Korro Bio is a biotechnology company focused on advancing genetic medicines by editing RNA to modulate biological pathways. It develops a proprietary platform, OPERA®, to deliver chemically modified RNA that targets precise changes inside cells. The company highlights its work on rare and complex diseases, such as alpha-1 antitrypsin deficiency, and emphasizes a pipeline of drug candidates derived from RNA editing strategies. Based on its messaging, Korro Bio operates in the biopharmaceutical sector with activities centered on therapeutics development and genetic medicines.

Recent News

Recent Deals

No recent deals for this company.

Key Team Members

Ram Aiyar

Chief Executive Officer & President

Loic Vincent

Chief Scientific Officer

Todd Chappell

Chief Operating Officer

Jean-François Formela

Co-Founder & Director

Nessan Bermingham

Co-Founder & Chairman

Key Facts

HQ Location

Cambridge, United States

Founded

2014

Employees

51 - 200

Status

Public

Website

https://korrobio.com